Comment
Author: Admin | 2025-04-28
Diminish the therapeutic effect of Lipegfilgrastim. Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Consider therapy modificationMesalamine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapyNatalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Avoid combinationNivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Consider therapy modificationOcrelizumab: May enhance the immunosuppressive effect of Immunosuppressants. Monitor therapyPalifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy. Consider therapy modificationPidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. Monitor therapyPimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Avoid combinationPromazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapyRoflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Consider therapy modificationSiponimod: Immunosuppressants may enhance the immunosuppressive effect of Siponimod. Monitor therapySipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Management: Evaluate patients to see if it is medically appropriate to reduce or discontinue therapy with immunosuppressants prior to initiating sipuleucel-T therapy. Consider therapy modificationSmallpox and Monkeypox Vaccine (Live): Immunosuppressants may diminish the therapeutic effect of Smallpox and Monkeypox Vaccine (Live). Monitor therapyTacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Avoid combinationTofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib. Management: Concurrent use with antirheumatic doses
Add Comment